In addition, calcimimetic and calcilytic drugs, which are positive and negative CaSR allosteric modulators, respectively, have been shown to be of potential benefit for these FHH and ADH disorders. This evidence concerns the gene CASR and familial hypocalciuric hypercalcemia.